Description
Nogapendekin alfa inbakicept is indicated with Bacillus Calmette-Guérin for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
Nogapendekin alfa inbakicept was approved for medical use in the United States in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
ANKTIVA (nogapendekin alfa inbakicept-pmln) solution, for intravesical use Initial U.S. Approval: 2024
See full prescribing information: Click Here
Get Access To Anktiva (nogapendekin alfa inbakicept-pmln) In India on request
Brand Name “Anktiva” or Generic Name “nogapendekin alfa inbakicept-pmln” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or you can call at 9891296838 or WhatsApp at 9891296838